Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Third-Party COVID-19-Specific CTLs for High-Risk Patients
NCT04765449Phase 1Completed
- Sponsor
- Thomas Jefferson University
- Start
- Sep 2021
- Primary completion
- Jul 2022
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of COVID-19-specific cytotoxic T lymphocytes in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Thomas Jefferson University. Primary endpoints: Safety of COVID-19-specific CTLs: Infusion Reactions at 48 hours, Safety of COVID-19-specific CTLs: Grade 4 Adverse Events at 14 days and 4 more. Started Sep 2021; status: completed.
02
Drugs
COVID-19-specific cytotoxic T lymphocytes
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04765449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04765449.